Literature DB >> 34142208

Correction to: The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them.

Pei-Yang Hu1, Xiao-Ming Fan2, You-Ni Zhang1,3,4, Shi-Bing Wang3,4, Wei-Jie Wan5, Hong-Ying Pan6, Xiao-Zhou Mou7,8.   

Abstract

Year:  2021        PMID： 34142208     DOI： 10.1007/s00253-021-11335-6

Source DB:  PubMed          Journal:  Appl Microbiol Biotechnol        ISSN： 0175-7598            Impact factor:   4.813


× No keyword cloud information.
  2 in total

Review 1.  The advent of oncolytic virotherapy in oncology: The Rigvir® story.

Authors:  Pēteris Alberts; Andra Tilgase; Agnija Rasa; Katrīna Bandere; Dite Venskus
Journal:  Eur J Pharmacol       Date:  2018-09-01       Impact factor: 4.432

2.  Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study.

Authors:  Simona Doniņa; Ieva Strēle; Guna Proboka; Jurgis Auziņš; Pēteris Alberts; Björn Jonsson; Dite Venskus; Aina Muceniece
Journal:  Melanoma Res       Date:  2015-10       Impact factor: 3.599
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.